All Stories

  1. Synaptic fidelity for drug development: is it time to move beyond glutamate release and receptors?
  2. Findings of PTSD-specific deficits in default mode network strength following a mild experimental stressor
  3. Ultrahigh-Field Magnetic Resonance Spectroscopy Findings Do Not Support Previous Brain Metabolite Findings in Major Depressive Disorder
  4. Correction: Psychosocial moderators of polygenic risk scores of inflammatory biomarkers in relation to GrimAge
  5. Psychosocial moderators of polygenic risk scores of inflammatory biomarkers in relation to GrimAge
  6. Neuroimaging-Based Classification of PTSD Using Data-Driven Computational Approaches: A Multisite Big Data Study from the ENIGMA-PGC PTSD Consortium
  7. Multimodal Imaging-Based Classification of PTSD Using Data-Driven Computational Approaches: A Multisite Big Data Study from the ENIGMA-PGC PTSD Consortium
  8. A mega-analysis of vertex and gyral cortical thickness differences in adults with and without PTSD
  9. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
  10. Imaging synaptic density in depression
  11. Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial
  12. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine
  13. A GIS framework for the application of the Land Degradation Neutrality concept in Mediterranean landscapes
  14. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial
  15. Proton Magnetic Resonance Spectroscopy in Post-Traumatic Stress Disorder—Updated Systematic Review and Meta-Analysis
  16. Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of relevance to depression, schizophrenia, and ketamine
  17. Dose-Related Effects of Ketamine for Antidepressant-Resistant Symptoms of Posttraumatic Stress Disorder in Veterans and Active Duty Military: A Double-blind, Randomized, Placebo-Controlled Multi-Center Clinical Trial
  18. Brain Functional Connectivity Scans, Acquired Years Before the Pandemic, Predict COVID-19 Infections in Older Adults: Data From 3,662 Participants
  19. Brain Networks Associated With COVID-19 Risk: Data From 3662 Participants
  20. Neurobiology of the Rapid Acting Antidepressant Effects of Ketamine: Impact and Opportunities
  21. A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants
  22. A Robust and Reproducible Connectome Fingerprint of Ketamine is Highly Associated with the Connectomic Signature of Antidepressants
  23. (2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?
  24. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
  25. Increased Cortical Thickness in Patients With Major Depressive Disorder Following Antidepressant Treatment
  26. Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression
  27. Pretreatment Brain Connectome Fingerprint Predicts Treatment Response in Major Depressive Disorder
  28. Determining the Hierarchical Architecture of the Human Brain Using Subject-Level Clustering of Functional Networks
  29. Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial
  30. Ketamine: A Paradigm Shift for Depression Research and Treatment
  31. The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder
  32. A Review of fMRI Affective Processing Paradigms Used in the Neurobiological Study of Posttraumatic Stress Disorder
  33. Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment
  34. Salience Network Disruption in U.S. Army Soldiers With Posttraumatic Stress Disorder
  35. Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment
  36. Are There Effective Psychopharmacologic Treatments for PTSD?
  37. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
  38. Topology of brain functional connectivity networks in posttraumatic stress disorder
  39. Default mode network abnormalities in posttraumatic stress disorder: A novel network-restricted topology approach
  40. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
  41. Determining the Hierarchical Architecture of the Human Brain Using Subject-Level Clustering of Functional Networks
  42. Stress Response Modulation Underlying the Psychobiology of Resilience
  43. Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ
  44. Locus Coeruleus Hyperactivity in Posttraumatic Stress Disorder: Answers and Questions
  45. Smaller Hippocampal Volume in Posttraumatic Stress Disorder: A Multisite ENIGMA-PGC Study: Subcortical Volumetry Results From Posttraumatic Stress Disorder Consortia
  46. Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass, and Behavioral Correlates
  47. Altered White Matter Diffusivity of the Cingulum Angular Bundle in Posttraumatic Stress Disorder
  48. Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients
  49. Neurobiological studies of trauma-related psychopathology: a public health perspective
  50. Multimodal Investigation of Network Level Effects Using Intrinsic Functional Connectivity, Anatomical Covariance, and Structure-to-Function Correlations in Unmedicated Major Depressive Disorder
  51. A Network-Based Neurobiological Model of PTSD: Evidence From Structural and Functional Neuroimaging Studies
  52. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
  53. Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology
  54. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study
  55. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies
  56. Neurobiology of posttraumatic stress disorder (PTSD): A path from novel pathophysiology to innovative therapeutics
  57. 67. Ketamine-induced Changes in Neural Noise and their Relationship to Psychosis-like Symptoms
  58. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression
  59. What’s the Buzz About Hydroxynorketamine? Is It the History, the Story, the Debate, or the Promise?
  60. Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment
  61. Targeting glutamate signalling in depression: progress and prospects
  62. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder
  63. Cortical thickness reduction in combat exposed U.S. veterans with and without PTSD
  64. Anterior hippocampal dysconnectivity in posttraumatic stress disorder: a dimensional and multimodal approach
  65. A New Journal: Addressing the Behavioral and Biological Effects of Chronic Stress
  66. Effects of Acute Confinement Stress-induced Hypothalamic-pituitary Adrenal Axis Activation and Concomitant Peripheral and Central Transforming Growth Factor-β1 Measures in Nonhuman Primates
  67. Combat Exposure Severity Is Associated With Reduced Cortical Thickness in Combat Veterans: A Preliminary Report
  68. The Association of PTSD Symptom Severity With Localized Hippocampus and Amygdala Abnormalities
  69. Chronic Pain and Chronic Stress: Two Sides of the Same Coin?
  70. Posttraumatic Stress Disorder and Depression Symptom Severities Are Differentially Associated With Hippocampal Subfield Volume Loss in Combat Veterans
  71. Reorganization of brain connectivity in obesity
  72. PTSD: from neurobiology to pharmacological treatments
  73. Ketamine Treatment and Global Brain Connectivity in Major Depression
  74. Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder
  75. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS
  76. Patterns of anterior versus posterior white matter fractional anistotropy concordance in adult nonhuman primates: Effects of early life stress
  77. Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies
  78. Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder
  79. Glutamate and norepinephrine interaction: Relevance to higher cognitive operations and psychopathology
  80. A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder
  81. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder
  82. Neurobiology of Maternal Stress: Role of Social Rank and Central Oxytocin in Hypothalamic–Pituitary Adrenal Axis Modulation
  83. Hippocampal volume and the rapid antidepressant effect of ketamine
  84. Amygdala-Hippocampal Volume and the Phenotypic Heterogeneity of Posttraumatic Stress Disorder
  85. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants
  86. In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5
  87. Rapid Acting Antidepressants
  88. Ketamine
  89. Glutamate Metabolism in Major Depressive Disorder
  90. Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene
  91. Morphometric hemispheric asymmetry of orbitofrontal cortex in women with borderline personality disorder: A multi-parameter approach
  92. A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy
  93. Ketamine
  94. Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight
  95. Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder
  96. Behavioral deficits, abnormal corticosterone, and reduced prefrontal metabolites of adolescent rats subject to early life stress
  97. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD
  98. Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients
  99. Riluzole effect on occipital cortex: A structural and spectroscopy pilot study
  100. Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
  101. Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeys
  102. Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates
  103. Early-life stress, corticotropin-releasing factor, and serotonin transporter gene: A pilot study
  104. Early-life stress and neurometabolites of the hippocampus
  105. The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates
  106. Suicide attempts and associated factors in older adults with schizophrenia
  107. Diffusion tensor imaging in studying white matter complexity: A gap junction hypothesis
  108. Community Integration and Associated Factors Among Older Adults With Schizophrenia
  109. Community Integration and Associated Factors Among Older Adults With Schizophrenia